TIAA CREF Investment Management LLC boosted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 44.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 61,187 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,691 shares during the period. TIAA CREF Investment Management LLC owned about 0.21% of Collegium Pharmaceutical worth $765,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Teachers Advisors LLC increased its holdings in Collegium Pharmaceutical by 98.8% in the 2nd quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock valued at $745,000 after purchasing an additional 29,617 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Collegium Pharmaceutical by 76.9% in the second quarter. Alliancebernstein L.P. now owns 27,600 shares of the specialty pharmaceutical company’s stock worth $345,000 after acquiring an additional 12,000 shares in the last quarter. Pier Capital LLC grew its stake in shares of Collegium Pharmaceutical by 8.1% in the second quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock worth $4,950,000 after acquiring an additional 29,594 shares in the last quarter. Bradley Foster & Sargent Inc. CT acquired a new position in shares of Collegium Pharmaceutical in the second quarter worth $403,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Collegium Pharmaceutical by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after acquiring an additional 39,656 shares in the last quarter. Hedge funds and other institutional investors own 83.96% of the company’s stock.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) opened at $14.61 on Tuesday. Collegium Pharmaceutical, Inc. has a 12 month low of $7.37 and a 12 month high of $18.02.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million during the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company’s revenue was up 2814.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.13) earnings per share. analysts predict that Collegium Pharmaceutical, Inc. will post -2.63 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/14/tiaa-cref-investment-management-llc-boosts-position-in-collegium-pharmaceutical-inc-coll.html.

Several equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, November 8th. Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $14.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. Collegium Pharmaceutical presently has an average rating of “Buy” and an average price target of $19.33.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.